News FDA approves Incyte's Pemazyre for rare bile duct cancer The FDA has approved Incyte's Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile duct.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
